{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"292"}],"units":"Participants"}],"description":"Safety by development of severe adverse events within 100 days of transplant","groups":[{"description":"Patients with refractory leukemia or MDS","id":"OG000","title":"High Risk Patients"},{"description":"Patients with Disease criteria: Acute myelogenous leukemia , Acute lymphocytic leukemia, Chronic myelogenous leukemia , NHL, Hodgkins, chronic lymphocytic leukemia, multiple myeloma, Acquired bone marrow failure syndromes, Myelodysplastic syndrome, Renal cell cancer,Chronic myeloproliferative disorder","id":"OG001","title":"Standard Risk Patients"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 100","title":"Serious Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}